혈관성형술용 풍선 시장 - 세계 예측(2026-2032년)

The Angioplasty Balloons Market is projected to grow by USD 3.78 billion at a CAGR of 5.24% by 2032.

Angioplasty balloons are central to percutaneous transluminal coronary angioplasty and peripheral vascular intervention, enabling clinicians to dilate narrowed or obstructed vessels, optimize lesion preparation, and restore blood flow in patients with coronary artery disease, peripheral artery disease, and other vascular stenoses. Demand is supported by the well-documented global cardiovascular disease burden, rising diabetes and obesity prevalence, population aging, and increased use of minimally invasive endovascular procedures. According to the World Health Organization, cardiovascular diseases remain the leading cause of death globally, while diabetes and hypertension continue to elevate risks for coronary and peripheral arterial complications. Product innovation is focused on drug-coated balloons, scoring and cutting balloons, high-pressure non-compliant balloons, specialty balloons for complex calcified lesions, and improved catheter deliverability for tortuous anatomy. The angioplasty balloon landscape is shaped by clinical evidence, reimbursement policies, regulatory scrutiny, hospital procurement standards, and physician preference for devices that improve procedural success while reducing restenosis, vessel trauma, and repeat intervention.

Transformative Shifts in the Angioplasty Balloon Landscape

The angioplasty balloon landscape is being reshaped by a shift from conventional vessel dilation toward lesion-specific and outcome-focused therapy. Drug-coated balloons have gained clinical relevance in selected coronary and peripheral indications because they deliver antiproliferative therapy without leaving a permanent implant, supporting treatment strategies where avoiding additional metal layers is preferred. At the same time, specialty balloons such as scoring, cutting, and ultra-high-pressure balloons are increasingly used for resistant, fibrotic, or calcified lesions that require controlled plaque modification before stenting or as part of a stent-free approach. Healthcare systems are prioritizing shorter procedure times, reduced hospitalization, fewer complications, and lower repeat revascularization rates, encouraging adoption of angioplasty balloon devices supported by robust clinical and real-world evidence. Regulatory expectations are rising around drug-device combination safety, biocompatibility, coating integrity, particulate release, sterilization validation, and long-term outcomes, while hospitals are strengthening value-based purchasing requirements that link device selection to safety, efficiency, and documented clinical performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across the angioplasty balloon ecosystem by improving diagnosis, procedural planning, device selection, workflow efficiency, and post-procedure surveillance. AI-enabled imaging analytics can support assessment of lesion length, vessel diameter, plaque morphology, calcium burden, and anatomical complexity using angiography, intravascular ultrasound, optical coherence tomography, computed tomography angiography, and electronic health record data. These capabilities can help physicians select balloon type, diameter, length, inflation strategy, and adjunctive therapy more consistently, particularly in complex coronary and peripheral interventions. In manufacturing and quality systems, AI can enhance process monitoring, defect detection, coating uniformity assessment, and predictive maintenance, supporting compliance with stringent medical device standards. In clinical operations, machine learning can improve patient risk stratification, identify restenosis risk patterns, and support registry-based evidence generation. However, adoption depends on validated algorithms, transparent clinical decision support, cybersecurity controls, interoperability with hospital systems, bias mitigation, and regulatory pathways that ensure AI tools are safe, explainable, and clinically meaningful.

Key Regional Insights

In Asia-Pacific, angioplasty balloon adoption is supported by high cardiovascular disease burden, expanding interventional cardiology capacity, rapid hospital infrastructure development, and growing access to catheterization laboratories in large urban centers, with China, India, Japan, South Korea, and Australia serving as major demand centers. North America demonstrates mature procedural adoption, advanced reimbursement frameworks, established use of complex endovascular techniques, and strong clinical guideline adherence, with device selection often shaped by evidence generation, hospital value analysis, and post-market safety surveillance. Europe benefits from structured regulatory oversight, strong clinical research networks, and widespread adoption of minimally invasive cardiovascular care, while procurement is influenced by health technology assessment, cost containment, and clinical outcome documentation. Latin America is characterized by rising need for cardiovascular and peripheral vascular interventions, uneven access between public and private healthcare systems, and increasing investment in specialist training and vascular centers, particularly in Brazil and Mexico. Africa faces higher access constraints due to limited catheterization infrastructure, workforce shortages, and affordability challenges, although urban referral hospitals and public-private investments are gradually improving availability of advanced cardiovascular interventions. The Middle East is expanding interventional capacity through tertiary care investment, medical tourism initiatives, and specialty cardiac centers, particularly across high-income Gulf healthcare systems where diabetes, obesity, and hypertension are prominent public health priorities.

Key Group Insights

NATO member countries overlap with several advanced cardiovascular markets and emphasize resilient medical supply chains, device safety, and healthcare system readiness, factors that have become more prominent amid geopolitical disruptions and medical technology supply chain risk management. G7 countries represent mature, high-standard healthcare systems where angioplasty balloon utilization is guided by clinical evidence, physician expertise, regulatory oversight, post-market surveillance, and value-based procurement. BRICS countries combine large patient populations with expanding procedure volumes and domestic healthcare modernization, but market access is shaped by price sensitivity, local manufacturing policies, reimbursement variation, and regional disparities in specialist care. The European Union presents a highly regulated and evidence-driven environment, where medical device regulation, post-market clinical follow-up, health technology assessment, and public procurement policies shape angioplasty balloon adoption. ASEAN demand for angioplasty balloons is influenced by expanding healthcare access, rising diabetes and hypertension prevalence, and increasing investment in cardiac catheterization services across major economies, although reimbursement diversity and specialist availability remain important adoption factors. GCC countries are strengthening interventional cardiology and vascular care through well-funded hospital systems, national health transformation programs, and high use of advanced medical technologies, supported by the region's significant cardiometabolic disease burden.

Key Country Insights

China is rapidly expanding advanced cardiovascular and peripheral vascular intervention capacity, supported by hospital modernization, domestic device development, centralized procurement reforms, and high patient volume linked to coronary artery disease, diabetes, and aging demographics. The United States remains a major center for angioplasty balloon use due to high cardiovascular disease prevalence, extensive catheterization laboratory networks, advanced reimbursement mechanisms, and strong adoption of coronary and peripheral interventions. Japan demonstrates high clinical sophistication, aging population dynamics, and strong adoption of precision endovascular techniques, while India is driven by rising coronary artery disease, diabetes, and urban hospital expansion, with price sensitivity and access outside major cities remaining central issues. Germany is a leading European hub for interventional cardiology, supported by high procedural capacity, specialist expertise, and broad hospital infrastructure, while the United Kingdom emphasizes evidence-based device selection through national clinical guidance, centralized procurement influences, and strong focus on outcomes and cost-effectiveness. Australia benefits from advanced specialist care, high-quality registries, and structured reimbursement, while France maintains advanced cardiovascular care delivery with strong regulatory and reimbursement oversight. South Korea combines advanced hospital infrastructure, strong clinical expertise, and rapid adoption of minimally invasive cardiovascular technologies, while Italy and Spain combine mature interventional practices with public health system budget discipline and regional procurement variation. Canada shows steady procedural demand supported by universal healthcare coverage, regionalized cardiac care systems, and evidence-based technology assessment, although access can vary by province and procedural capacity. Russia presents demand linked to cardiovascular disease burden and large geography, with access influenced by regional healthcare infrastructure and supply chain conditions. Brazil has one of Latin America's largest cardiovascular intervention bases, supported by major urban cardiac centers and a growing burden of diabetes, hypertension, and peripheral artery disease, while Mexico is expanding interventional cardiology access through private-sector growth and public hospital modernization, with affordability and reimbursement remaining key considerations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-backed innovation that addresses complex lesions, restenosis prevention, deliverability, procedural efficiency, and long-term patient outcomes. Development strategies should include robust clinical study design, real-world evidence programs, and post-market surveillance for drug-coated balloons, specialty balloons, and next-generation catheter platforms. Manufacturers should strengthen coating consistency, balloon compliance control, crossing profile optimization, trackability, and burst-pressure reliability while aligning quality systems with global regulatory requirements. Commercial teams should tailor market access strategies to local reimbursement, hospital procurement, and physician training needs, especially in regions with expanding interventional infrastructure. Partnerships with hospitals, academic investigators, and digital health developers can support procedural education, AI-enabled imaging integration, and registry-based outcome tracking. Supply chain resilience should be improved through diversified sourcing, validated manufacturing redundancy, and proactive risk monitoring for polymers, coatings, guidewire-compatible components, contrast-compatible materials, and sterilization capacity. Leaders should also invest in physician education for lesion-specific balloon selection, sizing, inflation protocols, and safe use practices, particularly for drug-coated, scoring, cutting, and high-pressure angioplasty balloon technologies.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and industry-relevant sources, including regulatory guidance, clinical practice guidelines, peer-reviewed medical literature, disease burden publications, hospital procurement trends, health technology assessment references, and medical device safety communications. The methodology emphasizes triangulation of clinical, regulatory, procedural, and macro-healthcare indicators to identify evidence-based patterns affecting angioplasty balloon adoption. Regional, group, and country insights are assessed through healthcare infrastructure maturity, cardiovascular disease prevalence, reimbursement environment, catheterization laboratory access, specialist availability, regulatory requirements, and documented trends in minimally invasive vascular intervention. The analysis excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on qualitative and data-backed drivers, barriers, innovation trends, and strategic implications.

Conclusion

Angioplasty balloons remain essential technologies in modern coronary and peripheral vascular intervention, with continued relevance driven by cardiovascular disease burden, minimally invasive treatment adoption, and demand for improved lesion-specific outcomes. The clinical landscape is moving toward drug-coated, specialty, and high-performance balloon platforms supported by stronger evidence, regulatory compliance, and real-world outcome tracking. Artificial intelligence, advanced imaging, and digital clinical workflows are strengthening procedural planning and post-procedure monitoring, while regional adoption continues to depend on reimbursement, infrastructure, clinician expertise, affordability, and supply continuity. Industry participants that combine clinically validated innovation, resilient supply chains, physician education, and region-specific access strategies will be better positioned to support safer, more effective, and more widely available angioplasty balloon interventions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Angioplasty Balloons Market, by Product Type

• 7.1. Introduction
• 7.2. Coronary Angioplasty Balloons
  • 7.2.1. Standard (Semi-Compliant) Balloons
  • 7.2.2. Non-Compliant Balloons
  • 7.2.3. Cutting and Scoring Balloons
• 7.3. Peripheral Angioplasty Balloons
  • 7.3.1. Drug-Coated Peripheral Balloons
  • 7.3.2. High-Pressure Peripheral Balloons
  • 7.3.3. Specialty Peripheral Balloons
• 7.4. Neurovascular Balloons
  • 7.4.1. Remodeling Balloons
  • 7.4.2. Occlusion Balloons

8. Angioplasty Balloons Market, by Material Type

• 8.1. Introduction
• 8.2. Nylon Balloons
• 8.3. Polyurethane Balloons
• 8.4. Polyethylene Terephthalate Balloons
• 8.5. Pebax Balloons

9. Angioplasty Balloons Market, by Balloon Diameter

• 9.1. Introduction
• 9.2. Small
• 9.3. Medium
• 9.4. Large

10. Angioplasty Balloons Market, by Sales Channel

• 10.1. Introduction
• 10.2. Direct Sales
• 10.3. Distributor and Dealer Sales
  • 10.3.1. Large-Scale Distributor Networks
  • 10.3.2. Independent Dealer Networks
• 10.4. Online and E-Procurement

11. Angioplasty Balloons Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Cardiac Centers
• 11.4. Hospitals
• 11.5. Specialty Clinics

12. Angioplasty Balloons Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Angioplasty Balloons Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Angioplasty Balloons Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Acrostak Int. Distr. Sarl
• 16.3. AngioDynamics, Inc.
• 16.4. Asahi Intecc Co., Ltd.
• 16.5. B. Braun SE
• 16.6. Balton Sp. z o.o.
• 16.7. Becton, Dickinson and Company
• 16.8. BIOTRONIK SE & Co. KG
• 16.9. Boston Scientific Corporation
• 16.10. BrosMed Medical Co., Ltd.
• 16.11. Cardinal Health, Inc.
• 16.12. Concept Medical Inc.
• 16.13. Cook Group Incorporated
• 16.14. Cordis
• 16.15. ENDOCOR GmbH
• 16.16. Hexacath
• 16.17. InSitu Technologies Inc.
• 16.18. iVascular S.L.U.
• 16.19. Kaneka Corporation
• 16.20. Koninklijke Philips N.V
• 16.21. Lepu Medical Technology(Beijing)Co., Ltd.
• 16.22. Medtronic PLC
• 16.23. Merit Medical Systems, Inc.
• 16.24. MicroPort Scientific Corporation
• 16.25. Nipro Medical Corporation
• 16.26. phenox GmbH
• 16.27. Scitech Medical
• 16.28. Teleflex Incorporated.
• 16.29. Terumo Medical Corporation